Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 4/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL143175 | 0.77 | ALDH1A1 (0.54) | F10 | |
| SCHEMBL31456623 | 0.76 | OPRM1 (0.41) | HTR1AF10CYP11B2 | |
| SCHEMBL10079094 | 0.76 | KDM4E (0.55) | TSHRPOLB | |
| SCHEMBL2645575 | 0.75 | DDB1 (0.41) | F10 | |
| SCHEMBL16812371 | 0.75 | PKM (0.44) | PKMCYP19A1CYP11B2ELANEPOLB | |
| SCHEMBL17979531 | 0.75 | MCHR1 (0.53) | — | |
| SCHEMBL15212468 | 0.75 | OPRM1 (0.41) | HTR1AF10 | |
| SCHEMBL142777 | 0.74 | F10 (0.44) | F10 | |
| SCHEMBL2539751 | 0.74 | F10 (0.39) | F10 | |
| SCHEMBL92819 | 0.74 | KDM4E (0.57) | PKMF10ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1518541-A | Phenyl derivatives | Ĭ��ר���ɷ�����˾ | 2004-08-04 | — | — | CN | claimed |
| US-20040087582-A1 | Phenyl derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2004-05-06 | — | — | US | claimed |
| EP-1351938-A1 | PHENYL DERIVATIVES | MERCK PATENT GmbH (DE) | 2003-10-15 | — | — | EP | claimed |
| WO-2002057236-A1 | PHENYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-07-25 | — | — | WO | claimed |
| EP-1893572-B1 | FACTOR XA INHIBITORS | MILLENNIUM PHARM INC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-8377974-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377974-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120178733-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-20120178733-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-07-12 | — | — | US | disclosed |
| US-8153670-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153670-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8129373-B2 | Carbonyl compounds | MERCK PATENT GMBH (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20070265259-A1 | Proline Derivatives | MERCK PATENT GMBH (DE) | 2007-11-15 | — | — | US | disclosed |
| US-7273867-B2 | Phenyl derivatives | MERCK PATENT GMBH (DE) | 2007-09-25 | — | — | US | disclosed |
| US-7273867-B2 | Phenyl derivatives | MERCK PATENT GMBH (DE) | 2007-09-25 | — | — | US | disclosed |
| US-7273867-B2 | Phenyl derivatives | MERCK PATENT GMBH (DE) | 2007-09-25 | — | — | US | disclosed |
| EP-1608645-B1 | PYRAZOLIDINE-1,2-DICARBOXYLDIPHENYLAMIDE DERIVATIVES AS COAGULATION FACTOR XA INHIBITORS FOR THE TREATMENT OF THROMBOSES | MERCK PATENT GMBH (DE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006002099-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| CN-1518541-A | Phenyl derivatives | Ĭ��ר���ɷ�����˾ | 2004-08-04 | — | — | CN | disclosed |
| US-20040087582-A1 | Phenyl derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265259-A1 | Proline Derivatives | F2, XPNPEP1, PRAP1 | HTR1A 1776/4885PKM 985/4885TSHR 1702/4885 |
| US-20120178733-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | HTR1A 1562/4885PKM 2122/4885TSHR 2852/4885 |
| US-20040087582-A1 | Phenyl derivatives | F2, F11, SERPINC1 | HTR1A 315/4885PKM 1736/4885TSHR 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.